Role of Everolimus in Highly Sensitized Patients

Model scores of the 29,894 trials active now.

Model score 34% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-01-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientseverolimusmg dlinfectionstherapy
  Phrases that lowered it: evaluatetolerabilityhistorysafetydrugs
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 94.6% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. NCT01023815 · started 2009 · scored riskier than 44% of active trials completed
• Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids NCT00658320 · started 2008 · scored riskier than 25% of active trials completed
• Everolimus Monotherapy as Immunosuppression After Liver Transplant NCT04063865 · started 2019 · scored riskier than 52% of active trials terminated
• Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants NCT01888432 · started 2013 · scored riskier than 65% of active trials completed
• Randomized Trial for Mixed Acute Rejection NCT00771875 · started 2008 · scored riskier than 92% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.